TriangleAtorvastatin (NCT05483010)
Atorvastatin trial for Clonal Cytopenia of Undetermined Significance (NCT05483010). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with lower-risk myelodysplastic syndromes or CCUS, a precursor condition with low blood counts and mutations. Patients must be transfusion-independent, have a qualifying mutation frequency ≥2%, and have avoided statins for one year.
The idea: researchers test whether statins reduce inflammation and slow expansion of abnormal blood-cell clones. Physicians choose atorvastatin eighty milligrams daily or rosuvastatin forty milligrams daily, for up to twelve months. Blood tests track changes.
This phase 2 study plans 16 patients. Amber Afzal leads at Washington University, St. Louis, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.